S-1/A: Yield10 Bioscience Files Amendment No. 2 to Form S-1 for Resale of Common Stock Issuable Upon Warrant Exercise

Yield10 Bioscience is filing an amendment to its S-1 registration statement to include adjusted financial data reflecting a reverse stock split and updates regarding its common stock trading on the OTC market, related to the potential resale of shares issuable upon the exercise of outstanding warrants.

Summary

• Yield10 Bioscience has filed Amendment No. 2 to its Form S-1 registration statement.
• The amendment includes selected financial data adjusted to reflect a 1:24 reverse stock split that occurred on May 2, 2024.
• It also provides updates regarding the company's common stock, which began trading on the over-the-counter market (OTC) operated by the OTC Markets Group on May 16, 2024, under the ticker symbol YTEN.
• The registration statement pertains to the proposed resale of up to 265,928 shares of Yield10 Bioscience common stock by selling security holders.
• These shares are issuable upon the exercise of warrants issued pursuant to an exchange agreement dated March 22, 2024.
• The company will not receive any proceeds from the sale of these shares by the selling security holders, but will receive proceeds from any cash exercise of the warrants.
• If all warrants are exercised for cash, Yield10 would receive approximately $2.7 million, which it intends to use for general corporate purposes, including working capital.
• The warrants have an exercise price of $10.32 per share and are subject to a blocker provision limiting the amount of shares that can be beneficially owned after exercise.
• The company's stock was delisted from the Nasdaq Capital Market on May 16, 2024, and now trades on the OTC market.
• Yield10 plans to apply for trading on the OTC-QB market.
• The company is focused on commercializing sustainable products using Camelina sativa, targeting omega-3 fatty acid production and biofuel feedstock markets.
• The company received regulatory approval from USDA-APHIS for two engineered Camelina lines, one producing EPA Omega-3 and the other producing EPA+DHA Omega-3.
• The company is also developing herbicide-tolerant Camelina varieties to improve agronomic performance and crop value.
• In March 2024, Yield10 entered into an exchange agreement with institutional investors, reducing the exercise price of existing warrants to $10.32 per share and issuing new warrants to purchase up to 265,928 shares.
• The gross proceeds from the warrant exercise were $1.4 million before deducting fees and expenses.

Sentiment

Score: 3

Explanation: The document contains both positive developments (regulatory approvals, potential warrant proceeds) and significant negative factors (delisting from Nasdaq, going concern warning, need for additional funding). The negative factors outweigh the positives, resulting in a low sentiment score.

Positives

• USDA-APHIS approval for engineered Camelina lines producing EPA and EPA+DHA Omega-3 indicates a favorable regulatory path.
• Development of herbicide-tolerant Camelina varieties can improve agronomic performance and crop value.
• The potential exercise of warrants could provide the company with $2.7 million in proceeds for general corporate purposes.
• The company has a license agreement with Vision Bioenergy Oilseeds, LLC that will provide $3.0 million in cash payments to Yield10.

Negatives

• The company's stock was delisted from the Nasdaq Capital Market and is now trading on the OTC market, which may result in a less liquid market and could depress the trading price.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company had cash, cash equivalents and short-term investments of $1.6 million as of March 31, 2024, which is believed to only provide funding for operations into the second quarter of 2024.
• The company is urgently evaluating and pursuing different strategies to obtain the required funding for its operations in the near term.

Risks

• The company's ability to continue as a going concern is dependent on raising substantial additional funds.
• The delisting from Nasdaq and trading on the OTC market may result in a more limited market and lack of liquidity for the company's securities.
• The company may be required to curtail its current development programs, cut operating costs, forego future development and other opportunities or even terminate its operations if it is unable to obtain funds when needed or on acceptable terms.
• The reverse stock split may not have the desired effect on the market price of the company's common stock.

Future Outlook

The company plans to continue development work with spring E3902 stack HT Camelina and winter stack HT Camelina during 2024, and aims for first commercial-scale production of EPA8 oil in 2026. The company also plans to bring both Omega-3 Camelina products forward in development with 2026 being the target for the first commercial-scale production of the EPA8 oil.

Industry Context

The document highlights Yield10's focus on the growing demand for omega-3 ingredients and biofuel feedstocks, driven by production constraints of traditional sources and government policies, respectively. The company positions Camelina as a sustainable platform crop to address these market opportunities.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• However, it mentions the growing demand for omega-3 ingredients in aquaculture and pet/animal feed, suggesting competition with traditional fish oil sources.
• In the biofuel sector, the document highlights the need for new oilseed cover crops like Camelina to meet growing demand, implying competition with other biofuel feedstocks.

Stakeholder Impact

• Shareholders face potential dilution from the issuance of shares upon warrant exercise.
• The delisting from Nasdaq may negatively impact the liquidity and value of shareholders' investments.
• Employees' job security is uncertain due to the company's financial difficulties and need to raise additional funds.
• Customers and suppliers may be concerned about the company's ability to fulfill its obligations due to its financial situation.
• Creditors face increased risk of non-payment if the company is unable to raise additional funds.

Next Steps

• The company plans to apply for trading on the OTC-QB market.
• The company intends to seek stockholder approval of the issuance of up to 265,928 shares of common stock in accordance with Nasdaq Listing Rule 5635(d) at its 2024 Annual Meeting of Stockholders on June 7, 2024.
• The company plans to continue development work with spring E3902 stack HT Camelina and winter stack HT Camelina during 2024.
• The company aims for first commercial-scale production of EPA8 oil in 2026.

Key Dates

Keywords

Yield10 Bioscience, Camelina, reverse stock split, OTC market, warrants, EPA, DHA, herbicide tolerance, delisting, financing